PUBLICATIONS DISCUSSED BY JOHN MACKEY, MD
Abstracts listed in order of their review in the audio program

Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.

Norris B et al. Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors. San Antonio Breast Cancer Symposium 2006;Abstract 2031.

Xu L et al. Capecitabine (X) + trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): Phase II trial results. San Antonio Breast Cancer Symposium 2006;Abstract 2065.

Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.

Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.

Publications Discussed by:

John Mackey, MD
Peter M Ravdin, MD, PhD
Clifford Hudis, MD
Additional Publications Discussed During the Program

Editor's Office